Director, Research and Clinical Development QA
![]() | |
![]() United States, Massachusetts, Cambridge | |
![]() 45 Sidney Street (Show on map) | |
![]() | |
How will your role help us transform hope into reality? You will be responsible for operational and some strategic management of the GCP QA activities. Reporting to Head of R&CD QA, you will have primary responsibility for QA oversight of GCP, and support GPvP (PV), GLP, and GCLP activities at Blueprint Medicines, its contract research organizations (CROs), and Investigator Sites to ensure that outsourced third parties are compliant and prepared for potential Sponsor and Regulatory Inspections. You will also ensure that the appropriate processes, systems, and activities are in place and performed to protect the rights, safety, and welfare of our clinical patients. You will also oversee, assess, and directly work to continuously improve quality processes and to support the state of compliance at Blueprint Medicines. This is an opportunity to mentor and develop the GCP QA function and ensure high quality execution of clinical trials from first in human through commercial marketing authorization as well as support of post-marketing activities. In this opportunity, you will manage cross-functional relationships with internal and external stakeholders and be the Quality Assurance representative to clinical teams. This role is required to be hands-on with internal and external partners. You will cross-train with other clinical GxP roles and execute those roles and responsibilities as deemed necessary by business needs. This role will also be responsible for representing R&CD QA on applicable governance charters and cross functional decision bodies. What will you do?
What minimum qualifications do we require?
What additional qualifications will make you a stronger candidate?
Why Blueprint? At Blueprint Medicines, we achieve impactful results because of our global crew of compassionate innovators - the Blue Crew. Through authentic relationships and our collective entrepreneurial spirit and action, we are each empowered to take ownership and execute with strategic prioritization. We put trust in our people to break through norms and conventions using their individual strengths and insights, which drives our success. This is the place where the extraordinary becomes reality, and you could be part of it. Patients are waiting. Are you ready to make the leap? Equity, Diversity, Inclusion and Affirmative Action At Blueprint Medicines, we foster a culture of equity, diversity and inclusion. A proud Equal Employment Opportunity and Affirmative Action employer, we consider all qualified applicants without regard to race, color, sex, gender identity or expression, sexual orientation, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, or any other characteristic protected under applicable law. We are also an E-Verify Employer. We will make reasonable accommodations, absent undue hardship, for qualified individuals with known disabilities. If you are an individual with a disability in need of an accommodation with the application or recruiting process, please reach out to TotalRewards@blueprintmedicines.com. For more information, please see ourEEO-AA Policy Statement, the E-Verify Participation Poster, the Right to Work Poster, and/or theEEO Know Your Rights Poster, as well as ourPay Transparency Statement. Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines, including bringing our medicine to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. #LI-Hybrid #LI-AQ1 |